Arcalyst® (rilonacept) – New indication
December 18, 2020 - The FDA approved Regeneron’s Arcalyst (rilonacept), for the maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg.
Download PDF
